Manufacturer Supply, High Purity, Commercial Production
Chemical Name: 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine
CAS: 666816-98-4
Intermediate for Linagliptin (CAS: 668270-12-0)
| Chemical Name |
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine |
| Synonyms |
8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1H-purine-2,6-dione; Linagliptin Intermediate C |
| CAS Number |
666816-98-4 |
| CAT Number |
RF-PI497 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C10H9BrN4O2 |
| Molecular Weight |
297.11 |
| Melting Point |
285℃ |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Off-White Powder |
| Water (K.F) |
≤0.50% |
| Residue on Ignition |
≤0.50% |
| Purity/Analysis Method |
≥99.0% (HPLC) |
| Max Single Impurity |
≤0.50% |
| Residual Solvents |
|
| Ethanol |
≤5000ppm |
| DMF |
≤3000ppm |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate for Linagliptin (CAS: 668270-12-0) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine (CAS: 666816-98-4) is an intermediate for Linagliptin (CAS: 668270-12-0). Linagliptin is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once daily use for the treatment of adults with type 2 diabetes mellitus. Linagliptin was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise.